Publications by authors named "N V Kharlamova"

In this study, we tested the skeletal human remains from the 18th - early 19th century Orthodox cemeteries in Irkutsk, Eastern Siberia, for tuberculosis-associated morphological alterations and Mycobacterium tuberculosis DNA. The morphologically studied bone collection included 591 individuals of mainly Caucasian origin. The molecular methods (IS6110-PCR and spoligotyping) suggested that at least four individuals (out of 15 TB-suspected, DNA-tested) were positive for the presence of M.

View Article and Find Full Text PDF

Objectives: High rates of anti-drug antibodies (ADA) to rituximab have been demonstrated in patients undergoing treatment for SLE. However, little is known with regard to their long-term dynamics, impact on drug kinetics and subsequent implications for treatment response. In this study, we aimed to evaluate ADA persistence over time, impact on circulating drug levels, assess clinical outcomes and whether they are capable of neutralizing rituximab.

View Article and Find Full Text PDF

Based on the epidemiological link between periodontitis and rheumatoid arthritis (RA), and the unique feature of the periodontal bacterium to citrullinate proteins, it has been suggested that production of anti-citrullinated protein antibodies (ACPA), which are present in a majority of RA patients, may be triggered in the gum mucosa. To address this hypothesis, we investigated the antibody response to a citrullinated peptide in relation to the autoimmune ACPA response in early RA, and examined citrulline-reactivity in monoclonal antibodies derived from human gingival B cells. Antibodies to a citrullinated peptide derived from (denoted CPP3) and human citrullinated peptides were analyzed by multiplex array in 2,807 RA patients and 372 controls; associations with RA risk factors and clinical features were examined.

View Article and Find Full Text PDF

Unlabelled: was to develop technologies for predicting the development of preeclampsia (PE) based on biomedical and molecular-genetic predictors and the calculation of individual risks for this pregnancy complication.

Materials And Methods: The study involved 457 pregnant women. Of them, 147 women had chronic arterial hypertension (CAH); 109 pregnant women had CAH and secondary preeclampsia (PE); 201 patients had PE.

View Article and Find Full Text PDF
Article Synopsis
  • Anti-drug antibodies (ADAs) can reduce the effectiveness and safety of treatments like rituximab used for chronic inflammatory conditions, particularly in diseases such as ANCA-associated vasculitis (AAV) and systemic lupus erythematosus (SLE).
  • The study aimed to determine the prevalence of ADAs against rituximab and identify risk factors in patients with SLE and AAV.
  • Results showed that while no AAV patients developed ADAs post-treatment, 37.8% of SLE patients did; ADA-positive SLE patients tended to be younger, have more active disease, and shorter disease duration compared to those without ADAs.
View Article and Find Full Text PDF